3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
14
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
12
Leukemia
5
Leukemia, Myeloid, Chronic-Phase
4
Leukemia, Myeloid, Accelerated Phase
4
Blast Crisis
4
Neoplasms
3
Leukemia, Myeloid, Acute
3
Carcinoma, Non-Small-Cell Lung
3
Gastrointestinal Stromal Tumors
2
Gastrointestinal Neoplasms
2
Thyroid Neoplasms
1
Small Cell Lung Carcinoma
1
Piebaldism
1
Philadelphia Chromosome
1
Neoplasms by Histologic Type
1
Myeloproliferative Disorders
1
Malignant Hepatobiliary Neoplasm
1
Lung Neoplasms
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid
1
Hematologic Diseases
1
Glioblastoma
1
Carcinoma, Pancreatic Ductal
1
Carcinoma, Medullary
1
Carcinoma
1
Burkitt Lymphoma
1
Bronchiolitis Obliterans Syndrome
1
Breast Neoplasms
1
Bone Marrow Diseases
1
Interventions
fludarabine phosphate
2
fludarabine
2
Whole-Body Irradiation
2
Tacrolimus
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mycophenolic Acid
2
Mesna
2
Melphalan
2
Cyclophosphamide
2
Busulfan
2
simtuzumab
1
ruxolitinib
1
ponatinib
1
pembrolizumab
1
nilotinib
1
ibrutinib
1
SCIO-469
1
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
1
Bone Marrow Transplantation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Bone Marrow Diseases
×
ponatinib
×
Clear all
NCT02467270
2026-03-17
OPTIC
Takeda
Phase 2
Completed
283 enrolled
31 charts